Latest Period
Q1 2026
Security Snapshot
BioRestorative Therapies, Inc. - Common Stock, $0.0001 par value (BRTX) Institutional Ownership
CUSIP: 090655606
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
10
Shares (Excl. Options)
677,096
Price
$0.27
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- BRTX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 677,096
- Total 13F value
- $184,219
- Portfolio coverage rank
- 0%
- Share change
- +399,261
- Value change
- +$40,329
- Number of holders
- 10
- Shares outstanding
- 27,267,374
- SEC-reported price per share
- $0.20
- Insider filing price
- $0.20
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BRTX - BioRestorative Therapies, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 090655606.
- 10 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 13 to 10 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $383,382 to $184,219.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 10 institutions filings for Q1 2026.
Security key
090655606
Latest holder period
Q1 2026
13F holders
10
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
BRTX full holder history
BioRestorative Therapies, Inc. SEC filings
BioRestorative Therapies, Inc. company facts
BioRestorative Therapies, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 090655606:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
BRTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Auctus Fund Management LLC | 9.9% | 0% | $647,873 | +$432,858 | 2,699,470 | +201% | Auctus Fund, LLC | 31 Mar 2026 |
| Alta Partners LLC | 7.7% | $2,162,467 | 1,787,163 | Alta Partners LLC | 13 Feb 2026 | |||
| ALSTODT LANCE | 16% | $2,201,520 | 1,236,809 | ALSTODT LANCE | 14 Feb 2025 | |||
| Silva Francisco | 15% | $2,130,338 | 1,196,819 | Silva, Francisco | 14 Feb 2025 | |||
| INTRACOASTAL CAPITAL, LLC | 4.1% | $1,051,243 | 922,143 | Mitchell P. Kopin | 11 Feb 2026 |
As of 31 Mar 2026, 10 institutional investors reported holding 677,096 shares of BioRestorative Therapies, Inc. - Common Stock, $0.0001 par value (BRTX). This represents 2.5% of the company’s total 27,267,374 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Latest
Q1 2026
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 677,096 | $184,219 | +$40,329 | $0.27 | 10 |
| 2025 Q4 | 327,161 | $383,382 | -$98,280 | $1.18 | 13 |
| 2025 Q3 | 379,488 | $545,311 | +$177,416 | $1.44 | 14 |
| 2025 Q2 | 247,366 | $412,419 | -$29,039 | $1.67 | 15 |
| 2025 Q1 | 281,898 | $501,776 | +$4,467 | $1.78 | 14 |
| 2024 Q4 | 283,612 | $405,563 | +$6,095 | $1.43 | 15 |
| 2024 Q3 | 272,185 | $471,917 | +$25,939 | $1.74 | 15 |
| 2024 Q2 | 256,145 | $519,973 | -$123,707 | $2.03 | 13 |
| 2024 Q1 | 384,984 | $530,968 | +$79,319 | $1.38 | 13 |
| 2023 Q4 | 312,403 | $540,922 | -$90,093 | $1.74 | 13 |
| 2023 Q3 | 362,913 | $648,725 | +$63,021 | $1.79 | 14 |
| 2023 Q2 | 322,637 | $1,422,829 | +$122,754 | $4.41 | 13 |
| 2023 Q1 | 298,901 | $1,016,792 | -$44,007 | $3.40 | 15 |
| 2022 Q4 | 327,690 | $899,848 | -$84,695 | $2.75 | 15 |
| 2022 Q3 | 358,231 | $1,156,301 | +$89,065 | $3.22 | 13 |
| 2022 Q2 | 330,604 | $974,116 | -$41,559 | $2.95 | 11 |
| 2022 Q1 | 344,602 | $1,801,209 | -$261,514 | $5.22 | 9 |
| 2021 Q4 | 396,349 | $1,720,900 | +$1,231,900 | $4.34 | 8 |